Novartis Venture Fund
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.
Business Model:
Revenue: $34.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Novartis Venture Fund Information
Geographic Data
Address: 355 Main St
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
9,316,027Website Global Rank
166Website Monthly Traffic
Twitter Followers
Description
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100&s;000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. Sectors New therapeutics &a; platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography USA/Canada Europe Switzerland Asia/Pacific
Contact Phone:
+16178713536
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2020 | Exo Therapeutics | Series A | 25M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 5/2009 | Visiogen | Series D | 40M |
| 9/2012 | F2G | Equity | 30M |
| 2/2005 | Covalys Biosciences | Series B | 2.6M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 9/2019 | Anokion | Series B | 40M |
| 11/2004 | Symetis | Series A | 9.6M |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 5/2013 | Eledon Pharmaceuticals | Series E | 35.5M |
| 6/2016 | F2G | Series E | 60M |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 8/2020 | GentiBio | Seed Round | 20M |
| 5/2000 | NovImmune | Series A | 14M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 4/2013 | Advanced Animal Diagnostics | Series B | 6M |
| 9/2016 | Rox Medical | Series E | 40M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 12/2006 | Aileron Therapeutics | Series A | 7M |
| 5/2014 | ImaginAb | Series B | 21M |
| 2/2009 | Alios BioPharma | Series A | 8.4M |
| 1/2019 | Occlufit | Venture Round | - |
| 2/2015 | Altimmune | Post-IPO Equity | 16M |
| 7/2010 | Euthymics Bioscience | Series A | 24M |
| 10/2015 | Galera Therapeutics | Series B | 37M |
| 6/2010 | Foldrx Pharmaceuticals | Venture Round | 29M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 7/2001 | Nereus Pharmaceuticals | Series B | 23.6M |
| 5/2007 | ProCertus BioPharm | Series A | 2.3M |
| 7/2009 | ProCertus BioPharm | Venture Round | 2.1M |
| 8/2019 | Renovacor | Series A | 11M |
| 1/2006 | EraGen Biosciences | Series A | 12M |
| 7/2007 | Neovacs | Venture Round | 17.9M |
| 6/2009 | Eledon Pharmaceuticals | Series D | 22M |
| 10/2006 | Biofisica | Series A | 5M |
| 7/2007 | Immune Targeting Systems | Series A | 7.1M |
| 5/2020 | mPharma | Series C | 0 |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 10/2012 | Thesan Pharmaceuticals | Series A | 16M |
| 9/2004 | Nura | Series A | 9.5M |
| 2/2019 | Anaveon | Series A | 35M |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 4/2011 | Akebia Therapeutics | Series B | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 5/2003 | GlycoMimetics | Series A | 4.3M |
| 10/2009 | Evolva | Series B | 27.8M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 7/2009 | Akebia Therapeutics | Series A | 25M |
| 8/2018 | Artios Pharma | Series B | 0 |
| 7/2011 | Myopowers Medical Technologies | Series B | 16M |
| 6/2015 | Myopowers Medical Technologies | Series C | 5.1M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 2/2012 | Celladon | Venture Round | 43M |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 6/2007 | BioRelix | Series A | 25.8M |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 6/2015 | Realeve | Series D | 43.2M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 6/2015 | Kanyos Bio | Venture Round | 16.4M |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 8/2006 | Kemia | Series C | 0 |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 5/2001 | AGY | Series B | 13M |
| 1/2018 | Oculis | Series B | 20.5M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 5/2002 | Kalypsys | Series A | 42M |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 5/2002 | ESBATech | Series A | 0 |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 10/2002 | MerLion Pharma | Series A | 0 |
| 1/2010 | Merus | Series B | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 2/2007 | Trellis Bioscience | Series B | 10M |
| 5/2001 | Polyphor | Venture Round | 9.3M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 6/2007 | Tepha | Series B | 0 |
| 2/2008 | Biofisica | Venture Round | 2.4M |
| 5/2017 | Lemonaid Health | Series A | 0 |
| 10/2011 | Realeve | Series C | 32M |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 10/2012 | Neurovance | Venture Round | 7M |
| 4/2014 | Neurovance | Series A | 6.3M |
| 8/2021 | GentiBio | Series A | 157M |
| 11/2007 | Ascent Therapeutics | Series A | 19M |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 9/2020 | Novellus | Series C | 57M |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 1/2000 | Viron Therapeutics | Series A | - |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 8/2004 | GlycoMimetics | Series A | 5.1M |
| 9/2009 | PharmAbcine | Series A | 6M |
| 6/2010 | NanoPowers | Series A | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 7/2017 | NeuroVia | Series A | 14M |
| 2/2016 | Galera Therapeutics | Series B | 0 |
| 8/2014 | Galera Therapeutics | Series A | 4.7M |
| 6/2006 | GlycoMimetics | Series B | 0 |
| 3/2007 | Phenomix | Series C | 55M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 10/2009 | Nabriva Therapeutics | Venture Round | 0 |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 6/2007 | Aileron Therapeutics | Series B | 7M |
| 6/2009 | Alios BioPharma | Series A | 24M |
| 5/2009 | NovImmune | Venture Round | 0 |
| 7/2009 | Avila Therapeutics | Series B | 30M |
| 4/2007 | Protemix | Series A | 14.5M |
| 4/2012 | Advanced Animal Diagnostics | Series B | 4M |
| 8/2004 | Evolva | Series A | 14.8M |
| 10/2013 | Opsona | Series C | 0 |
| 4/2013 | Opsona | Series C | 0 |
| 3/2022 | Epsilogen | Series B | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 10/2020 | Rappta Therapeutics | Series A | 10.6M |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 6/2009 | Opsona | Series B | 4.6M |
| 9/2016 | Inflazome | Series A | 17M |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 2/2006 | Catalyst Biosciences | Series B | 30M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 4/2008 | Aileron Therapeutics | Series C | 10.5M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 12/2018 | Annexon Biosciences | Series C | 75M |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 11/2022 | DJEL | Venture Round | 139.4M |
| 1/2015 | Binx Health | Series C | 0 |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 9/2011 | Eledon Pharmaceuticals | Series D | 23M |
| 12/2006 | Evolva | Series A | 10.3M |
| 3/2011 | Euthymics Bioscience | Series A | 4M |
| 8/2006 | ESBATech | Series B | 41M |
| 12/2008 | Diagnoplex | Series A | 8.3M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 1/2021 | TScan Therapeutics | Series C | 100M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 10/2009 | Covagen | Seed Round | - |
| 11/2010 | Covagen | Series A | 6.3M |
| 1/2017 | Binx Health | Series D | 0 |
| 10/2004 | Miikana Therapeutics | Series A | 3M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2019 | Adicet Bio | Series B | 0 |
| 3/2005 | Evolva | Series A | 2.6M |
| 7/2009 | Intellikine | Series B | 51M |
| 8/2008 | ESBATech | Series B | 22M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 6/2007 | Cequent Pharmaceuticals | Series A | 9M |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 5/2014 | Anokion | Series A | 37.5M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 11/2020 | Catalym | Series B | 59.3M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 4/2011 | ProCertus BioPharm | Series A | 1.7M |
| 8/2010 | Anchor Therapeutics | Series B | 10M |
| 4/2008 | FORMA Therapeutics | Series A | 4M |
| 1/2016 | Adicet Bio | Series A | 51M |
| 2/2007 | Omeros | Series E | 0 |
| 3/2015 | Galera Therapeutics | Series A | 4.7M |
| 12/2005 | Santhera Pharmaceuticals | Series B | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 11/2021 | Capstan Therapeutics | Seed Round | 63M |
| 3/2010 | Immune Targeting Systems | Series A | 13.2M |
| 6/2006 | NovImmune | Series B | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 3/2012 | ImaginAb | Series A | 12.5M |
| 10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
| 10/2009 | Bicycle Therapeutics | Seed Round | - |
| 10/2014 | Quartet Medicine | Series A | 17M |
| 10/2013 | Merus | Series B | 42.2M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 12/2017 | Aelin Therapeutics | Series A | 31.8M |
| 1/2010 | MicroCHIPS | Venture Round | 16.5M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 8/2014 | YourBio Health | Series B | 16M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 5/2019 | Cala Health | Series C | 0 |
| 12/2012 | Galera Therapeutics | Series A | 11M |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 11/2009 | Oxagen | Series C | 0 |
| 3/2020 | Akouos | Series B | 105M |
| 8/2018 | Akouos | Series A | 25.1M |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 7/2019 | TScan Therapeutics | Series B | - |
| 7/2009 | Symetis | Series B | 0 |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 5/2006 | Foldrx Pharmaceuticals | Series B | 43M |
| 4/2014 | Binx Health | Series B | 0 |
| 5/2015 | Realeve | Series D | 38M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 4/2007 | MicroCHIPS | Venture Round | 13.4M |
| 12/2019 | Arctos Medical | Seed Round | 0 |
| 3/2011 | Advanced Animal Diagnostics | Series B | 11M |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 3/2022 | Epsilogen | Series B | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
